Skip to content
Screener

Rhythm Pharmaceuticals, Inc. RYTM Other income, net (Note 6)

Other income, net (Note 6) at other companies

Viking Therapeutics logo
Viking TherapeuticsVKTX
$5.8M-41.1%
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
-$24.23M-28,279%
TG Therapeutics logo
TG TherapeuticsTGTX
$5.13M+83.7%
Arrowhead Research logo
Arrowhead ResearchARWR
-$1.61M-467%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$1M-50.0%
BridgeBio Pharma logo
BridgeBio PharmaBBIO

Segments

By segment

See full
Single reportable segment-$1.7M-165%

Other financials

Income statement

See full
Revenue$60.1M+83.8%
Gross profit$53.0M+82.3%
Operating income-$52.4M-11.4%
Net income-$55.6M-12.4%
EPS (diluted)-$0.83-2.5%

Balance sheet

See full
Cash & equivalents$62.1M-41.4%
Total debt$112.3M-1.1%
Total equity$122.9M+549%
Total assets$442.3M+14.4%

Cash flow

See full
Operating cash flow-$44.2M-9.5%
CapEx$238.3K
Free cash flow-$29.2M-2.4%

Valuation

See full
Market cap$7.72B+29.1%
Enterprise value$7.77B+30.4%
P/S35.5×-2.7×

Profitability

See full
Gross margin89.4%-0.2pp
Operating margin-90.9%-19.8pp
Net margin-93.3%-18.2pp
FCF margin-61.5%-14.1pp

Returns & leverage

See full
Return on equity-285.8%-68.9pp
Debt / equity0.9×-5.1×
Current ratio4.2×+0.9×

Where this comes from

Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.

The source filing: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:15 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-030549
Line itemThree months ended March 31, 20262025
Total costs and expenses112,47379,708
Loss from operations(52,361)(47,004)
Other income (expense):
Other income (expense), net(1,704)(644)
Interest expense(4,583)(5,409)
Interest income3,5543,639
Total other income (expense), net(2,733)(2,414)
Loss before income taxes(55,094)(49,418)

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Rhythm Pharmaceuticals, Inc.'s other income, net (note 6)?
Rhythm Pharmaceuticals, Inc. (RYTM) reported other income, net (note 6) of -$1.7M in Q1 2026.
How has Rhythm Pharmaceuticals, Inc.'s other income, net (note 6) changed year-over-year?
Rhythm Pharmaceuticals, Inc.'s other income, net (note 6) decreased by 164.6% year-over-year, from -$644K to -$1.7M.
What is the long-term trend for Rhythm Pharmaceuticals, Inc.'s other income, net (note 6)?
Over 4 years (2021 to 2025), Rhythm Pharmaceuticals, Inc.'s other income, net (note 6) has grown at a -66.5% compound annual growth rate (CAGR), from $100M to $1.26M.
What does other income, net (note 6) mean?
This captures miscellaneous financial items that fall outside the scope of core operating activities, such as foreign exchange gains or losses, minor investment income, or non-recurring legal settlements. It serves as a catch-all for peripheral financial events that do not stem from the primary business operations. Investors monitor this to isolate core earnings from transient or incidental financial fluctuations.

Ask your AI about Rhythm Pharmaceuticals, Inc.'s other income, net (note 6).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude